Altimmune(NASDAQ) ALT

Current Price$2.77

Market Cap$538.69M

Since IPO (2017)-99%

5 Year-69%

1 Year-33%

1 Month-6%

Altimmune last closing stock price
Metric	Price	Date
Last close	USD 2.77	2026-07-24

Altimmune stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.48%	USD 2.87	2026-07-17
1 month	-6.1%	USD 2.95	2026-06-24
3 month	-2.81%	USD 2.85	2026-04-24
Year to date	-23.27%	USD 3.61	2025-12-31
1 year	-32.6%	USD 4.11	2025-07-24
3 year	-7.67%	USD 3.00	2023-07-25
5 year	-68.81%	USD 8.88	2021-07-23
Since inception	-98.83%	USD 237.30	2017-05-05

Altimmune Financials at a Glance

Market Cap

$538.69M

Revenue (TTM)

$36.00K

Net Income (TTM)

-$91.08M

EPS (TTM)

-$0.94

P/E Ratio

-2.95

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$2.77

Volume

1,911,556.492

Open

$2.85

Price

$2.77

Volume

1,911,556.492

Open

$2.85

Previous Close

$2.77

Daily Range

$2.76 - $2.89

52-Week Range

$2.56 - $6.44

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$2.77

Volume

1,911,556.492

Open

$2.85

Previous Close

$2.77

Daily Range

$2.76 - $2.89

52-Week Range

$2.56 - $6.44

Estimated Earnings Date

Aug 11, 2026

ALT News

Patient being weighed by a medical professional

If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy

Alex CarchidiJun 29, 2024

Pharmacist handing prescription medication to a customer.

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

David Jagielski, CPAApr 20, 2024

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

Adam SpataccoApr 9, 2024

Page 1

ALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Altimmune

Altimmune develops medicines for obesity and liver health. These products help patients reduce fat and manage weight. The company focuses on serious and unmet medical needs.

A Look at the Lab

Pemvidutide: An experimental drug that acts on two hormones to reduce liver fat and lower appetite.
HepTcell: An immunotherapy product candidate designed for patients with long-term Hepatitis B infections.
MASH Treatments: Research focused on liver inflammation and scarring, known as metabolic dysfunction-associated steatohepatitis.
Alcohol-Related Care: Medicines developed to reduce alcohol cravings and repair liver damage from excessive drinking.

New Directions and Deals

Acquired Spitfire Pharma Inc. in July 2019 to obtain the rights for its primary drug candidate.
Partnered with Adocia S.A. in December 2024 to develop an oral version of its main treatment.
Secured Fast Track status from the FDA for treatments targeting liver disease and alcohol misuse.
Reached an agreement with regulators in late 2025 to begin a Phase 3 clinical study in 2026.

What Sets Altimmune Apart

Altimmune uses a balanced approach that triggers two metabolic pathways to treat both the liver and body weight. This design aims to protect muscle mass, which is a key differentiator in the competitive obesity market.

The 2025 Scorecard

Revenue was $26,000 in Q4 2025, up 420% from $5,000 in Q4 2024.
Operating loss reached $28.9 million in Q4 2025, a 16.2% worsening from Q4 2024.
Net loss hit $27.4 million in Q4 2025, an 18% worsening year-over-year.
Free cash flow was negative $19.4 million in Q4 2025, worsening 6.5% from Q4 2024.

The Final Word

Altimmune has evolved from early research into a clinical-stage specialist in metabolic and liver health. Its focus on unmet needs in alcohol-associated diseases helps define its path in the biotechnology sector.

AI Generated • May 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Jerome B. Durso

Website

www.altimmune.com

Headquarters

Gaithersburg, MD 20878, US

ALT Financials

Key Financial Metrics (TTM)

Gross Margin

-41519.44%

Operating Margin

-269216.67%

Net Income Margin

-253002.78%

Return on Equity

-42.57%

Return on Capital

-36.26%

Return on Assets

-27.14%

Earnings Yield

-33.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$538.69M

Shares Outstanding

194.47M

Volume

1.91M

Avg. Volume

3.72M

Financials (TTM)

Gross Profit

-$14.95M

Operating Income

-$96.92M

EBITDA

-$88.27M

Operating Cash Flow

-$71.64M

Capital Expenditure

-$32.00K

Free Cash Flow

-$71.67M

Cash & ST Invst.

$331.54M

Total Debt

$35.85M

Altimmune Performance Analysis

Altimmune annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD -68,000	N/A
2023	2023-12-31	USD 426,000	N/A
2024	2024-12-31	USD 20,000	-95.3%
2025	2025-12-31	USD 41,000	105.0%

Altimmune sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	420.0%
Q1	2026-03-31	-100.0%

Altimmune annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.81	-23.2%
2023	2023-12-31	USD -1.66	-8.0%
2024	2024-12-31	USD -1.34	-19.4%
2025	2025-12-31	USD -1.00	-25.3%

Altimmune sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-3.8%
Q3	2025-09-30	22.2%
Q4	2025-12-31	-28.6%
Q1	2026-03-31	33.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$23.00K

-560.0%

Gross Margin

0.00%

N/A

Market Cap

$538.69M

N/A

Market Cap/Employee

$9.45M

N/A

Employees

N/A

Net Income

-$22.56M

-15.3%

EBITDA

-$21.47M

-6.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$331.54M

+121.3%

Total Debt

$35.85M

+2158.8%

Accounts Receivable

$265.00K

-89.2%

Inventory

$0.00

N/A

Long Term Debt

$35.58M

+2551.4%

Short Term Debt

$265.00K

+8.2%

Return on Assets

-27.14%

N/A

Return on Invested Capital

-29.88%

N/A

Free Cash Flow

-$20.96M

-24.5%

Operating Cash Flow

-$20.94M

-24.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AURAAura Biosciences, Inc.

AURAAura Biosciences, Inc.$7.05-2.08%

LRMRLarimar Therapeutics, Inc.

LRMRLarimar Therapeutics, Inc.$4.00-0.25%

DBVTDBV Technologies S.A.

DBVTDBV Technologies S.A.$13.63-1.66%

AMRNAmarin Corporation plc

AMRNAmarin Corporation plc$13.55-0.37%

ACIUAC Immune S.A.

ACIUAC Immune S.A.$2.23-0.45%

ANNXAnnexon, Inc.

ANNXAnnexon, Inc.$5.22-1.51%

ANROAlto Neuroscience, Inc.

ANROAlto Neuroscience, Inc.$26.78-0.26%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

NUNu Holdings

NUNu Holdings$14.09-0.01%

TAT&T

TAT&T$24.13+0.05%

Questions About ALT

What is the current price of Altimmune?

Altimmune is trading at $2.77 per share.

What is the 52-week range for Altimmune?

Over the past 52 weeks, Altimmune has traded between $2.56 and $6.44.

How much debt does Altimmune have?

As of the most recent reporting period, Altimmune reported total debt of $35.85M.

How much cash does Altimmune have on hand?

Altimmune reported $97.64M in cash and cash equivalents in its most recent financial results.

What is Altimmune’s dividend yield?

Altimmune does not currently have a dividend yield.

Altimmune(NASDAQ) ALT

Altimmune Financials at a Glance

ALT News

Why Altimmune Was Such a Robustly Healthy Stock on Thursday

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics

If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

ALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Altimmune

A Look at the Lab

New Directions and Deals

What Sets Altimmune Apart

The 2025 Scorecard

The Final Word

ALT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Altimmune Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALT

What is the current price of Altimmune?

What is the 52-week range for Altimmune?

How much debt does Altimmune have?

How much cash does Altimmune have on hand?

What is Altimmune’s dividend yield?

Premium Investing Services